StockTipsArenaBeta

BUY Mankind Pharma Limited — Raja Venkatraman

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

byRaja VenkatramanHorizon: 1–3 months30 Sept 2026via LiveMint Markets

Entry₹2,550Stated
Target₹2,800
Total upside +9.80% (call closed)
Stop loss₹2,440-4.31% risk
Exit₹2,4408 Oct 2026, 11:22 am
Stop-loss hit-4.31%
Follow Raja Venkatraman for new calls(26% target hit, 70 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 2 active Short-term calls on MANKINDSee 84 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 8 Oct 2026
4 supporting3 neutral3 opposing
Supports the BUY call (4)

2 other SEBI-registered advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·29 Sept · 1w ago

Mankind Pharma shares up 10% in just 4 sessions; Kotak upgrades the stock - Target, share price trend

NewsLivemint·22 Sept · 2w ago

(opens in new tab)

Mankind Pharma shares get an upgrade from Kotak; Price target among top five on the street

NewsCnbc-Tv18·22 Sept · 2w ago

(opens in new tab)

6 advisors have active long-term BUY calls on this stock

Advisor consensus · adjacent horizon·22 Sept · 2w ago

Neutral / worth noting (3)

Mankind Pharma To Give Rs 1 Crore To Flydubai Captain Smit Machchhar, Family For Averting Flight Disaster

NewsNdtv-Profit·3 Oct · 4d ago

(opens in new tab)

Mankind Pharma Gets 68.21 ESG Rating From Niche99 In Leader Category

NewsGoogle News·15 Sept · 3w ago

(opens in new tab)

Mankind Pharma to attend three investor conferences in September 2026

NewsGoogle News·11 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (3)

1 advisor has an active long-term SELL call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·7 Oct · yesterday

Mankind Pharma auditor resigns as subsidiary Bharat Serums enters liquidation

NewsGoogle News·28 Sept · 1w ago

(opens in new tab)

Mankind Pharma's subsidiary Bharat Serums and Vaccines sees auditor resignation amid liquidation

NewsGoogle News·28 Sept · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Raja Venkatraman

Every call and its outcome